Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415-453. Abstract
NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version8.2017. www.nccn.org. Accessed November 17, 2017.
Naidoo J, Drilon A. Molecular diagnostic testing in non-small cell lung cancer. Am J Hematol Oncol. 2014;10:4-11.
Ofiara LM, Navasakulpong A, Beaudoin S, et al. Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. Front Oncol. 2014;4:253.
Padmanabhan V, Steinmetz HB, Rizzo EJ, et al. Improving adequacy of small biopsy and fine-needle aspiration specimens for molecular testing by next-generation sequencing in patients with lung cancer: a quality improvement study at Dartmouth-Hitchcock Medical Center. Arch Pathol Lab Med. 2017;141:402-409. Abstract
Aisner DL, Rumery MD, Merrick DT, et al. Tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the University of Colorado Experience. Arch Pathol Lab Med. 2016. [Epub ahead of print]
Roy-Chowdhuri S, Stewart J. Preanalytic variables in cytology. Lessons learned from next-generation sequencing -- the MD Anderson experience. Arch Pathol Lab Med. 2016. [Epub ahead of print]
Tian SK, Killian JK, Rekhtman N, et al. Optimizing workflows and processing of cytologic samples for comprehensive analysis by next-generation sequencing. Memorial Sloan Kettering Cancer Center experience. Arch Pathol Lab Med. 2016. [Epub ahead of print]
Tafe LJ. Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets. Virchows Arch. 2017;471:155-164.
Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rocilentinib (CO-1686) in plasma-genotyped T790M-positive NSCLC patients. J Clin Oncol. 2015;34 (suppl). Abstract 8001.
Sheikine Y, Rangachari D, McDonald DC, et al. EGFR testing in advanced non small-cell lung cancer, a mini-review. Clin Lung Cancer. 2016;17:483-492. Abstract
Wakelee HA, Gadgeel SM, Goldman JW, et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from NSCLC pts treated with rocilentinib. J Clin Oncol. 2016;34(suppl). Abstract 9001.
Reck M, Hagiwara K, Han B, et al. Investigating the utility of circulating-free tumor derived DNA in plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in European and Japanese patients with advanced NSCLC: ASSESS Study. Ann Oncol. 2015;26(35O_PR)i57-i61.
Bordi P, Del Re M, Danesi R, et al. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:584-597. Abstract
Watanabe M, Kawaguchi T, Isa S-I, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Can Res. 2015;21:3552-3560.
Guardant360. Clinical test for solid tumor. www.ncbi.nlm.nih.gov/gtr/tests/GTR000527948/. Accessed November 23, 2017.
PGD. Personal Genome Diagnostics. http://www.personalgenome.com/pharma-biotech-companies/liquid-biopsy/. Accessed November 23, 2017.
FoundationACT® https://www.foundationmedicine.com/genomic-testing/foundation-act. Accessed November 23, 2017.
TrovaGene. https://www.trovagene.com/. Accessed November 23, 2017.
Normanno N, Denis MG, Thress KS, et al. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8:12501-12516. Abstract
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461. Abstract
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non small-cell lung cancer. NEJM. 2015;372:2018-2028. Abstract
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. NEJM. 2015;373:123-135. Abstract
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. NEJM. 2015; 373:1627-1639. Abstract
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomized controlled trial. Lancet. 2016;387:1837-1846. Abstract
Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35:2781-2789. Abstract
Antonia S, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. NEJM. 2017. [Epub ahead of print]
ClinialTrials.gov. Avelumab in non-small cell lung cancer (JAVELIN Lung 200). NCT02395172. www.clinicaltrials.gov. Accessed November 23, 2017.
Hirsch F, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208-222. Abstract
Scheel AH, Baenfer G, Bretton G, et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology. 2017. [Epub ahead of print]
Adam J, Rouquette I, Damotte D, et al. Multicentric French Harmonization Study for PD-L1 IHC testing in NSCLC. J Thorac Oncol. 2017;12(1 suppl):S11-S12.
Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017;23:3585-3591. Abstract
Bettegowda C, Sausen M, Leary R, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222-230. Abstract
Kang Q, Henry NL, Paoletti C, et al. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and Cell Save blood collection tubes. Clin Biochem. 2016;49:1354-1360. Abstract
Medina Diaz I, Nocon A, Mehnert DH, et al. Performance of Streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016;11:e0166354.
Miotke L, Lau T, Rumma RT, et al. High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR. Analyti Chem. 2014;86:2618-2624.
Weerts MJ, Marion R, Helmijr JC, et al. Somatic tumor mutations detected by targeted next generation sequencing in minute amounts of serum-derived cell-free DNA. Sci Rep. 2017;7:2136.
Rennert H, Eng K, Zhang T, et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genome Med. 2016. [Epub ahead of print]
Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rocilentinib in plasma-genotyped T790M-positive NSCLC patients. J Clin Oncol. 2015;34(suppl). Abstract 8001.
Sheikine Y, Rangachari D, Mc Donald DC, et al. EGFR testing in advanced non-small-cell lung cancer, a mini-review. Clin Lung Cancer. 2016;17:483-492. Abstract
Wakelee HA, Gadgeel SM, Goldman JW, et al. Epidermal growth factor genotyping of matched urine, plasma, and tumor tissue from NSCLC pts treated with rociletinib. J Clin Oncol. 2016;34(suppl). Abstract 9001.
Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:3375-3382. Abstract
Wei Z, Shah N, Deng C, et al. Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus. 2016;5:531.
Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2:1014-1022. Abstract
Khan J, Pritchard CC. Tissue is the issue for diagnosis of EGFR T790M mutation. J Thorac Oncol. 2016;11:e91-e92. Abstract
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388. Abstract
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-128. Abstract 7521.
Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742. Abstract
Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246. Abstract
Sequist LV, Yang J, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334. Abstract
Yang J, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). Presented at: 2014 American Society of Clinical Oncology Annual Meeting; May 30-June 03, 2014; Chicago, IL. Abstract 8004.
Yang J, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015:16;141-151. Abstract
Wu YL, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-222. Abstract
Yu H, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247. Abstract
Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Can Res. 2009;15:2630-2636.
Wakelee H, Melnikova V, Karlovich C, et al. A highly sensitive next generation sequencing platform for detection of NSCLC EGFR T790M mutation in urine and plasma. Presented at: The International Association for the Study of Lung Cancer (IASLC) World Conference in Lung Cancer 2017. MA08.01.
cobas® EGFR Mutation Test v2. https://molecular.roche.com/assays/cobas-egfr-mutation-test-v2-us-ivd. Accessed November 23, 2017.
Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung CA. 2015;90:509-515.
Ricciuti B, Baglivo S, Paglialunga L, et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol. 2017;9:387-403. Abstract
Wu Y, Liu H, Shi X, et al. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis. Lung Cancer. 2015;88:246-253. Abstract
Jänne PA, Yang J, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-1699. Abstract
Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:3375-3382. Abstract
Mok TS, Wu Y-L, Han MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629-640. Abstract
Tsao AS, Scagliotti GV, Bunn PA, et al. Scientific advances in lung cancer 2015. J Thorac Oncol. 2016;11:613-638. Abstract
Paweletz CP, Sacher AG, Raymond CK, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Can Res. 2016;22:915-922.
Mack P, Banks KC, Riess JW, et al. Clinical utility of circulating tumor DNA (ctDNA) analysis by digital next generation sequencing of over 5,000 advanced NSCLC patients (ID6096). Presented at: IASLC WCLC 2016. Abstract OA 06.01.
Mu¨ller JN, Falk M, Talwar J, et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. J Thorac Oncol. 2017;12:1503-1511. Abstract
Ramalingam SS, Reungwetwattana T, Chewaskulyoung B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Presented at: European Society for Medical Oncology 2017 Congress; September 8-12, 2017; Madrid, Spain. LBA2_PR.
Gray JE, Okamoto I, Sriuranpong V, et al. Osimertinib vs SoC EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA): plasma ctDNA analysis. Presented at: World Conference Lung Cancer 2017. Abstract OA 05.02.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

H. Jack West, MD

Medical Oncology Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington

Disclosures

Disclosure: H. Jack West, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ARIAD Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: ARIAD Pharmaceuticals, Inc.

Dr West does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr West does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Laura J. Tafe, MD

Associate Professor, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth; Assistant Director, Laboratory for Clinical Genomics and Advanced Technologies, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Disclosures

Disclosure: Laura J. Tafe, MD, has disclosed no relevant financial relationships.

Dr Tafe does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Tafe does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christina Lockwood, PhD, DABCC, DABMGG

Associate Professor, Department of Laboratory Medicine; Director, Genetics and Solid Tumors Laboratory, University of Washington, Seattle, Washington

Disclosures

Disclosure: Christina Lockwood, PhD, DABCC, DABMGG, has disclosed no relevant financial relationships.

Ms Lockwood does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Lockwood does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Heather Wakelee, MD

Professor of Medicine, Oncology, Stanford University, Stanford Cancer Institute, Stanford, California

Disclosures

Disclosure: Heather Wakelee, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ACEA Biosciences, Inc.; Genentech, Inc.; Helsinn Therapeutics, Inc; Peregrine Pharmaceuticals Inc.; Pfizer Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP/MedImmune Inc; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly;.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacyclics, Inc.; Xcovery Vision

Dr Wakelee does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Wakelee does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Davecia R. Cameron, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CME/Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

Authors: H. Jack West, MD; Christina Lockwood, PhD, DABCC, DABMGG; Laura J. Tafe, MD; Heather Wakelee, MD
CME / ABIM MOC Released: 12/21/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/21/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for pathologists, oncologists, pulmonologists, and radiologists.

The goals of this activity are to help guide treatment selection in patients with advanced non-small cell lung cancer (NSCLC) by closing the gap related to the use of biomarker testing and to improve physician knowledge and understanding, which can contribute to improved quality of patient care.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data supporting the use of biomarkers to guide treatment selection in patients with advanced NSCLC
Have greater competence related to
- Selecting the most appropriate testing strategy for detection of mutations or protein expression to allow accurate characterization of a patient's NSCLC
- Accurate reporting of biomarker test results to other members of the care team to help guide optimal treatment selection throughout the continuum of a patient's disease

Disclosures

Moderator

H. Jack West, MD

Medical Oncology Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington

Disclosures

Disclosure: H. Jack West, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ARIAD Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: ARIAD Pharmaceuticals, Inc.

Dr West does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr West does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Laura J. Tafe, MD

Associate Professor, Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth; Assistant Director, Laboratory for Clinical Genomics and Advanced Technologies, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Disclosures

Disclosure: Laura J. Tafe, MD, has disclosed no relevant financial relationships.

Dr Tafe does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Tafe does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christina Lockwood, PhD, DABCC, DABMGG

Associate Professor, Department of Laboratory Medicine; Director, Genetics and Solid Tumors Laboratory, University of Washington, Seattle, Washington

Disclosures

Disclosure: Christina Lockwood, PhD, DABCC, DABMGG, has disclosed no relevant financial relationships.

Ms Lockwood does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Lockwood does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Heather Wakelee, MD

Professor of Medicine, Oncology, Stanford University, Stanford Cancer Institute, Stanford, California

Disclosures

Disclosure: Heather Wakelee, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ACEA Biosciences, Inc.; Genentech, Inc.; Helsinn Therapeutics, Inc; Peregrine Pharmaceuticals Inc.; Pfizer Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP/MedImmune Inc; Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly;.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacyclics, Inc.; Xcovery Vision

Dr Wakelee does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Wakelee does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Davecia R. Cameron, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CME/Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

Authors: H. Jack West, MD; Christina Lockwood, PhD, DABCC, DABMGG; Laura J. Tafe, MD; Heather Wakelee, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/21/2017

Valid for credit through: 12/21/2018, 11:59 PM EST

processing....

Q&A

Educational Impact Challenge

The goals of this activity are to help guide treatment selection in patients with advanced NSCLC by closing the gap related to the use of biomarker testing and to improve physician knowledge and understanding, which can contribute to improved quality of patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

PDF Downloads

Print
Like Tweet

Developed through a partnership between Medscape and the Association for Molecular Pathology.

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

H. Jack West, MD

Panelists

Laura J. Tafe, MD

Christina Lockwood, PhD, DABCC, DABMGG

Heather Wakelee, MD

Editor

Davecia R. Cameron, MS

CME/Content Reviewer

Nafeez Zawahir, MD

Peer Reviewer

CME / ABIM MOC

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

Target Audience and Goal Statement

Disclosures

Moderator

H. Jack West, MD

Panelists

Laura J. Tafe, MD

Christina Lockwood, PhD, DABCC, DABMGG

Heather Wakelee, MD

Editor

Davecia R. Cameron, MS

CME/Content Reviewer

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Diagnostic Strategies in Advanced NSCLC: Guiding Treatment Decisions Through Pathology

Educational Impact Challenge

PDF Downloads